FM
fazen.markets
healthcare·esfritzh

Amesite Signs 2,000-Patient NurseMagic Enterprise Deal

0h ago|5 min readStandard
FM

Fazen Markets

Source: SEC EDGAR

Written by AI from a primary source ·

amesiteamstnursemagichealthcare-aiai-documentation
Sponsoredby Fazen Capital

AiX — Free Expert Advisor

Trades XAUUSD on autopilot. Verified Myfxbook performance. Free forever.

Myfxbook verified No subscription XAUUSD M15
Get Free EA

Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. AiX is informational software — not investment advice. Past performance does not guarantee future results.

Key Takeaways

  • 1Amesite added a 2,000-patient enterprise customer, extending its upmarket push but disclosing no contract value to size the revenue impact.

Partner

Trade the Markets Discussed in This Article

Regulated Broker Competitive Spreads

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Amesite Inc. (Nasdaq: AMST) announced on 16 November 2026 a new NurseMagic enterprise agreement with a healthcare organization serving approximately 2,000 patients, the company's latest contract win among large healthcare organizations. The company said the deal ramps revenue, user base and patient census, and follows a 2,700-census enterprise win in May 2026, a trading partner agreement in March 2026 and the December 2025 launch of its AI-native NurseMagic EMR. Amesite did not disclose contract value, term length or per-seat pricing.

Context — why this matters now

Amesite's strategy is to move upmarket through the non-acute and post-acute healthcare segments. The company describes a progression from hospice and home care into skilled nursing, senior living, and enterprise workflows serving Medicare and Medicaid populations. Each step reuses the same AI-native infrastructure rather than requiring a new platform build, which the company frames as the reason it can deploy customer-specific capabilities in days.

The new contract extends that progression into healthcare services for rural Medicare and Medicaid populations. Amesite cites 64.5 million rural Americans in this segment, including 17.8 million Medicaid enrollees and 11.8 million Medicare beneficiaries. Using projected 2026 spending per enrollee, the company estimates $232.9 billion in annual Medicaid spending and $224.0 billion in Medicare spending across those groups, or roughly $456.9 billion combined.

Amesite puts the combined estimated U.S. market size of segments represented by customers in its portfolio at approximately $1.5 trillion. That figure is the company's own estimate, not an audited market study, and it frames the commercial thesis behind the deal.

The prior comparable the company gives is its 2,700-census enterprise customer win in May 2026. That deal was larger on census. The new 2,000-patient agreement is smaller in headcount terms, but the company said median customer census at signing has increased 4x from 2025 to 2026, which it presents as evidence that it is attracting larger organizations over time.

Macro conditions are not discussed in the report. No financing terms, rate assumptions or reimbursement-rate figures were provided, and the company did not say whether the contract is billed per patient, per user or per site.

Data — what the numbers show

The disclosed figures are operational rather than financial. The contract covers approximately 2,000 patients. The May 2026 precedent covered a 2,700 census. Amesite said median customer census at signing rose 4x between 2025 and 2026.

On engineering throughput, Kalie Wortinger, Head of Engineering, said the company now ships more than 13 times as much code each quarter as it did in the first quarter of 2025, with a further 37% increase in the third quarter of 2026 over the second quarter, without adding engineers. Both figures are company statements.

MetricPrior disclosureNew disclosure
Enterprise census2,700 (May 2026)~2,000 patients
Median census at signing2025 baseline4x higher in 2026
Code shippedQ1 2025 baseline13x per quarter; +37% Q3 2026 vs Q2 2026

The company says NurseMagic reduces documentation time from 20 minutes to 20 seconds, a claim it has repeated across prior releases. NurseMagic is used by over 100 professions, per the company, across 50 states and 21 countries, with translations into more than 50 languages.

No revenue figure, margin, backlog, ARR or contract value was disclosed for this agreement. Investors therefore cannot size the deal against Amesite's reported financials from this announcement alone.

Analysis — what it means for markets / sectors / tickers

For AMST holders, the signal is directional rather than quantitative. A new enterprise logo in a new sub-segment, rural Medicare and Medicaid services, supports the company's claim that it can keep expanding into adjacent care settings without rebuilding its core platform. The absence of contract value means the revenue impact cannot be modeled from this release.

The second-order read is on healthcare documentation and ambient clinical AI more broadly. Amesite positions NurseMagic as sitting on top of existing EMR systems rather than replacing them, which lowers the switching cost for buyers and shortens sales cycles. That positioning competes with transcription-first vendors and with EMR-native documentation modules.

A limitation worth flagging: patient census is not the same as revenue. A 2,000-patient organization may generate less recurring revenue than a 2,700-census customer depending on seat count, documentation volume and pricing tier. Amesite did not bridge census to dollars, so the comparison across the two wins is not like-for-like.

A second risk is concentration. Amesite's portfolio is built from a relatively small number of enterprise agreements, and each new win moves the revenue base. Losing or failing to renew any single large customer would be material.

Positioning is difficult to assess because the report gives no float, short interest or institutional ownership data. What the release does show is that management is emphasizing enterprise sales conversion and engineering velocity as the two proof points for its growth story.

Outlook — what to watch next

Amesite did not provide guidance, a revenue target or a date for reporting results. The next concrete checkpoint will be the company's next quarterly filing or earnings release, where the revenue contribution from enterprise wins would appear. No date for that release was given in the report.

The May 2026 2,700-census win and this 2,000-patient agreement together give a rough cadence of large-organization signings. Whether that cadence continues into the next quarter is the operational question.

On the product side, the company pointed to NurseMagic Record, which adds ambient and mobile recording including offline capture with automatic synchronization. Adoption of that module among existing enterprise customers would be a second signal.

No price levels, moving averages or valuation metrics were disclosed, and none are asserted here.

Frequently Asked Questions

What does the Amesite NurseMagic deal mean for retail investors?

It is an operational milestone, not a financial disclosure. Amesite announced the customer, the patient census and the segment, but not the contract value, term or pricing structure. Retail investors cannot calculate revenue impact from this release alone. The relevant number will appear in a future quarterly report, if the company breaks out enterprise contributions.

Why did Amesite not disclose the contract value?

The company did not say. Enterprise healthcare agreements often include confidentiality provisions, but Amesite gave no reason in the announcement. Investors should treat the omission as a gap rather than infer a size. The only quantitative anchors provided are the 2,000-patient census and the earlier 2,700-census win.

What is the rural Medicare and Medicaid market Amesite is targeting?

Amesite cites 64.5 million rural Americans, including 17.8 million Medicaid enrollees and 11.8 million Medicare beneficiaries. Using projected 2026 per-enrollee spending, the company estimates $232.9 billion in annual Medicaid spending and $224.0 billion in Medicare spending, about $456.9 billion combined. These are company estimates, not independent market data.

Bottom Line

Amesite added a 2,000-patient enterprise customer, extending its upmarket push but disclosing no contract value to size the revenue impact.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.

Sponsored — AiX

Trade XAUUSD on autopilot — free Expert Advisor

AiX is our free MetaTrader 5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. XAUUSD breakout engine.

Get Free EA

PartnerPosition yourself for the macro moves discussed above

Start Trading
Share

Stay informed

Get market analysis delivered to your inbox.

Join 18,500+ investors

Sponsored

Ready to trade the markets?

Open a demo account in 30 seconds. No deposit required.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Related